Clinical Outcomes of Aflibercept in AMD and DME

What clinical outcomes support aflibercept treatment of wet AMD and diabetic macular edema?

Aflibercept treatment for wet AMD and diabetic macular edema is supported by visual acuity improvements equivalent to ranibizumab and superior to laser photocoagulation, significant anatomical improvements including central retinal thickness reductions and diabetic retinopathy severity improvements, clinically meaningful quality of life gains, and a safety profile comparable to other anti-VEGF agents with the advantage of less frequent dosing.

Abstract

Aflibercept treatment for wet age-related macular degeneration produces visual acuity outcomes equivalent to ranibizumab, with both treatments showing similar mean BCVA changes (within 0.5 letters) and approximately 32% of patients gaining ≥15 letters at one year. Anatomical outcomes were also similar, with comparable proportions achieving dry retina (RR 1.06, 95% CI 0.98 to 1.14) and equivalent choroidal neovascularization area reductions. For diabetic macular edema, aflibercept demonstrated statistically significant superiority over laser photocoagulation, with mean BCVA gains of 10.5-13.6 letters compared to -0.5 to 1.2 letters for laser (p<0.0001), and central retinal thickness reductions of 183-195 μm versus 66-73 μm for laser (p<0.0001). At 148 weeks, 35.8-42.9% of aflibercept-treated eyes gained ≥15 letters versus 13.6-18.9% with laser. Aflibercept showed non-inferiority to bevacizumab (mean improvement 15.0 versus 14.0 letters, p=0.37) and better anatomical outcomes than ranibizumab in real-world practice (central subfield thickness reduction -114.4 μm versus -87.8 μm, p<0.01). Quality of life improved meaningfully in both conditions, with NEI VFQ-25 total score gains of +6.11 points in DME and clinically significant improvements across multiple subscales in wet AMD. The safety profile was comparable to other anti-VEGF agents, with serious systemic adverse events similar to ranibizumab (RR 0.99, 95% CI 0.79 to 1.25) and no new safety signals identified in long-term use. The every-8-weeks maintenance dosing regimen after initial loading reduced treatment burden compared to monthly regimens while maintaining efficacy.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Records from Elicit search

• n = 200
• Papers screened using: Target Population, Intervention, Clinical Outcomes, Study Design, Follow-up Duration, Aflibercept Analysis, Study Quality and Accessibility, Study Scope
• n = 200 Papers screened out
• n = 190 Papers included for extraction

Characteristics of included studies

The systematic review included 10 sources examining aflibercept treatment for wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These comprised randomized controlled trials, observational studies, and systematic reviews.

The studies represented diverse designs, with five focusing on wet AMD and five on DME. Most studies were randomized controlled trials, with comparators including ranibizumab, bevacizumab, and laser photocoagulation. Follow-up durations ranged from 52 weeks to 3 years. Only two studies had full texts available for detailed extraction (J. Heier et al., 2012 and J. Carrasco et al., 2021).

Visual Acuity Outcomes in Wet AMD

Aflibercept demonstrated substantial and sustained visual acuity improvements in wet AMD across multiple studies. In the VIEW trials comparing aflibercept to ranibizumab, all aflibercept regimens were within 0.5 letters of ranibizumab for mean change in BCVA, demonstrating clinical equivalence.

Study Outcomes

The real-world meta-analysis reported a mean BCVA of 62.55 ETDRS letters at 2 years, with 47.39% of patients achieving visual acuity of ≥70 letters.

Visual Acuity Outcomes in Diabetic Macular Edema

Aflibercept demonstrated consistent superiority over laser photocoagulation and non-inferiority to other anti-VEGF agents in DME.

Study Outcomes

Long-term outcomes remained robust. At 148 weeks, mean BCVA gains with aflibercept were significantly better than those with laser control (p<0.0001).

Anatomical Outcomes

Aflibercept produced significant anatomical improvements in both wet AMD and DME.

Central Retinal Thickness Changes:

Diabetic retinopathy severity also improved with aflibercept treatment. Greater proportions of eyes treated with aflibercept showed improvement of ≥2 steps in the Diabetic Retinopathy Severity Scale compared to laser control in both VISTA and VIVID studies.

Vision-Related Quality of Life

Quality of life assessments demonstrated clinically meaningful improvements with aflibercept treatment. In wet AMD, the NEI VFQ-25 scores showed similar improvements across all subscales over 52 weeks for aflibercept 2q8 and ranibizumab.

Quality of Life Measure

The improvements were more pronounced for near activities than for distant activities, suggesting significant impact on daily functioning.

Safety Profile

The safety profile of aflibercept was generally favorable and comparable to other anti-VEGF agents. In both wet AMD and DME trials, ocular and systemic adverse events were similar across aflibercept and ranibizumab treatment groups.

The real-world meta-analysis indicated no new safety signals were found in long-term use, though comprehensive safety data were limited.

Treatment Regimens

Aflibercept was administered at a dose of 2 mg across all studies. Two primary dosing regimens emerged:

• Every 4 weeks regimen (2q4): Monthly injections throughout the treatment period.

• Every 8 weeks regimen (2q8): 3-5 initial monthly doses followed by maintenance dosing every 8 weeks.

The eight-week dosing regimen represented reduced treatment requirements compared to monthly regimens and offered the potential to reduce treatment burden and risks from frequent injections.

Comparative Effectiveness

Aflibercept demonstrated non-inferiority to ranibizumab in wet AMD and superiority to laser photocoagulation in DME, with comparable effectiveness to bevacizumab.

Key Findings:

• Versus Ranibizumab in Wet AMD: Aflibercept was clinically equivalent, with visual acquity outcomes and proportion of eyes achieving dry retina similar between treatments.
• Versus Laser in DME: Aflibercept showed higher BCVA gains and better central retinal thickness reductions.
• Versus Bevacizumab in DME: Non-inferiority in visual outcomes.

Key Limitations

• Risk of bias concerns (e.g., funding source, blinding, population characteristics).
• Missing data or loss to follow-up may limit the strength of the findings.
• Short follow-up duration for observed long-term outcomes.